Progestiinipohjaisia

Progestiinipohjaisia is a Finnish term that translates to "progestin-based" in English. It refers to medical preparations, contraceptive methods, and therapeutic regimens that contain synthetic derivatives of progesterone, the natural steroid hormone produced by the ovaries. Progestins are used to mimic or modulate the actions of endogenous progesterone, influencing the menstrual cycle, pregnancy maintenance, and various physiological processes.

In contraception, progestin-only options include the mini‑pill, contraceptive implants, subdermal rods, and hormonal intrauterine devices that release progestin over several years. These methods primarily work by thickening cervical mucus, inhibiting sperm penetration, and suppressing ovulation. They are suitable for women who cannot use estrogen due to risk factors such as thrombosis or breastfeeding.

Beyond birth control, progestiinipohjaisia preparations are employed in hormone replacement therapy to alleviate menopausal symptoms, in the management of endometriosis to reduce pain and proliferation, and in certain gynecological treatments such as progesterone‑based hemostasis for postpartum hemorrhage. The selection of a particular progestin—levonorgestrel, norethindrone, medroxyprogesterone acetate, or drospirenone—depends on intended use, side‑effect profile, and patient tolerability.

The therapeutic efficacy of progestin-based treatments depends on its receptor affinity, metabolic stability, and the presence of co‑administrated estrogen or other agents. While generally well tolerated, they can provoke side effects such as mood changes, weight gain, and breast tenderness. Regulatory agencies worldwide assess each progestin for safety, efficacy, and quality before approving pharmaceutical use.